Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial.

Casha S, Rice T, Stirling DP, Silva C, Gnanapavan S, Giovannoni G, Hurlbert RJ, Yong VW.

J Neurotrauma. 2018 Aug 15;35(16):1918-1928. doi: 10.1089/neu.2018.5899.

PMID:
30074872
2.

Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis.

Camara-Lemarroy CR, Metz L, Smith EE, Dunn JF, Yong VW.

Front Neurol. 2018 Jun 19;9:475. doi: 10.3389/fneur.2018.00475. eCollection 2018. No abstract available.

3.

Automated Slide Scanning and Segmentation in Fluorescently-labeled Tissues Using a Widefield High-content Analysis System.

Poon CC, Ebacher V, Liu K, Yong VW, Kelly JJP.

J Vis Exp. 2018 May 3;(135). doi: 10.3791/57440.

PMID:
29781988
4.

In Vivo MR Imaging of Tumor-Associated Macrophages: The Next Frontier in Cancer Imaging.

Yang R, Sarkar S, Yong VW, Dunn JF.

Magn Reson Insights. 2018 Apr 26;11:1178623X18771974. doi: 10.1177/1178623X18771974. eCollection 2018. Review.

5.

Pro-inflammatory roles of chondroitin sulfate proteoglycans in disorders of the central nervous system.

Stephenson EL, Yong VW.

Matrix Biol. 2018 Apr 25. pii: S0945-053X(18)30148-3. doi: 10.1016/j.matbio.2018.04.010. [Epub ahead of print] Review.

PMID:
29702175
6.

The extracellular matrix: Focus on oligodendrocyte biology and targeting CSPGs for remyelination therapies.

Pu A, Stephenson EL, Yong VW.

Glia. 2018 Mar 30. doi: 10.1002/glia.23333. [Epub ahead of print] Review.

PMID:
29603376
7.

Chondroitin sulfate proteoglycans as novel drivers of leucocyte infiltration in multiple sclerosis.

Stephenson EL, Mishra MK, Moussienko D, Laflamme N, Rivest S, Ling CC, Yong VW.

Brain. 2018 Apr 1;141(4):1094-1110. doi: 10.1093/brain/awy033.

PMID:
29506186
8.

Deficient Surveillance and Phagocytic Activity of Myeloid Cells Within Demyelinated Lesions in Aging Mice Visualized by Ex Vivo Live Multiphoton Imaging.

Rawji KS, Kappen J, Tang W, Teo W, Plemel JR, Stys PK, Yong VW.

J Neurosci. 2018 Feb 21;38(8):1973-1988. doi: 10.1523/JNEUROSCI.2341-17.2018. Epub 2018 Jan 23.

PMID:
29363580
9.

Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis.

Koch MW, Ilnytskyy Y, Golubov A, Metz LM, Yong VW, Kovalchuk O.

Eur J Neurol. 2018 Apr;25(4):651-658. doi: 10.1111/ene.13565. Epub 2018 Feb 13.

PMID:
29316044
10.

Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic.

Faissner S, Mishra M, Kaushik DK, Wang J, Fan Y, Silva C, Rauw G, Metz L, Koch M, Yong VW.

Nat Commun. 2017 Dec 19;8(1):1990. doi: 10.1038/s41467-017-02119-6.

11.

Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy.

Plemel JR, Michaels NJ, Weishaupt N, Caprariello AV, Keough MB, Rogers JA, Yukseloglu A, Lim J, Patel VV, Rawji KS, Jensen SK, Teo W, Heyne B, Whitehead SN, Stys PK, Yong VW.

Glia. 2018 Feb;66(2):327-347. doi: 10.1002/glia.23245. Epub 2017 Oct 25.

PMID:
29068088
12.

Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?

Faissner S, Mahjoub Y, Mishra M, Haupeltshofer S, Hahn JN, Gold R, Koch M, Metz LM, Ben-Hur T, Yong VW.

Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811. [Epub ahead of print]

PMID:
28857721
13.

Remyelination therapies: a new direction and challenge in multiple sclerosis.

Plemel JR, Liu WQ, Yong VW.

Nat Rev Drug Discov. 2017 Sep;16(9):617-634. doi: 10.1038/nrd.2017.115. Epub 2017 Jul 7. Review.

PMID:
28685761
14.

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.

Metz LM, Li DKB, Traboulsee AL, Duquette P, Eliasziw M, Cerchiaro G, Greenfield J, Riddehough A, Yeung M, Kremenchutzky M, Vorobeychik G, Freedman MS, Bhan V, Blevins G, Marriott JJ, Grand'Maison F, Lee L, Thibault M, Hill MD, Yong VW; Minocycline in MS Study Team.

N Engl J Med. 2017 Jun 1;376(22):2122-2133. doi: 10.1056/NEJMoa1608889.

15.

Stop inflammation and you stop neurodegeneration in MS - YES.

Yong HY, Yong VW.

Mult Scler. 2017 Sep;23(10):1320-1321. doi: 10.1177/1352458517707266. Epub 2017 May 2. No abstract available.

PMID:
28463075
16.

Gestational bisphenol-A exposure lowers the threshold for autoimmunity in a model of multiple sclerosis.

Rogers JA, Mishra MK, Hahn J, Greene CJ, Yates RM, Metz LM, Yong VW.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4999-5004. doi: 10.1073/pnas.1620774114. Epub 2017 Apr 24.

17.

Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells.

Sarkar S, Mirzaei R, Zemp FJ, Wei W, Senger DL, Robbins SM, Yong VW.

Cancer Res. 2017 Jun 15;77(12):3231-3243. doi: 10.1158/0008-5472.CAN-16-2171. Epub 2017 Apr 17.

18.

Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.

Poon CC, Sarkar S, Yong VW, Kelly JJP.

Brain. 2017 Jun 1;140(6):1548-1560. doi: 10.1093/brain/aww355. Review.

PMID:
28334886
19.

Unique spectral signatures of the nucleic acid dye acridine orange can distinguish cell death by apoptosis and necroptosis.

Plemel JR, Caprariello AV, Keough MB, Henry TJ, Tsutsui S, Chu TH, Schenk GJ, Klaver R, Yong VW, Stys PK.

J Cell Biol. 2017 Apr 3;216(4):1163-1181. doi: 10.1083/jcb.201602028. Epub 2017 Mar 6.

20.

T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.

Mirzaei R, Sarkar S, Yong VW.

Trends Immunol. 2017 Feb;38(2):104-115. doi: 10.1016/j.it.2016.11.005. Epub 2016 Dec 7. Review.

PMID:
27964820
21.

Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.

Hahn JN, Kaushik DK, Mishra MK, Wang J, Silva C, Yong VW.

J Immunol. 2016 Nov 15;197(10):3850-3860. Epub 2016 Oct 12.

22.

Evaluating Soluble EMMPRIN as a Marker of Disease Activity in Multiple Sclerosis: Studies of Serum and Cerebrospinal Fluid.

Kaushik DK, Yong HY, Hahn JN, Silva C, Casha S, Hurlbert RJ, Jacques FH, Lisak R, Khan O, Ionete C, Larochelle C, Prat A, Bar-Or A, Yong VW.

PLoS One. 2016 Oct 11;11(10):e0163802. doi: 10.1371/journal.pone.0163802. eCollection 2016.

23.

MRI monitoring of monocytes to detect immune stimulating treatment response in brain tumor.

Yang R, Sarkar S, Korchinski DJ, Wu Y, Yong VW, Dunn JF.

Neuro Oncol. 2017 Mar 1;19(3):364-371. doi: 10.1093/neuonc/now180.

24.

Myeloid cells - targets of medication in multiple sclerosis.

Mishra MK, Yong VW.

Nat Rev Neurol. 2016 Sep;12(9):539-51. doi: 10.1038/nrneurol.2016.110. Epub 2016 Aug 12. Review.

PMID:
27514287
25.

Regenerative Capacity of Macrophages for Remyelination.

Rawji KS, Mishra MK, Yong VW.

Front Cell Dev Biol. 2016 May 20;4:47. doi: 10.3389/fcell.2016.00047. eCollection 2016. Review.

26.

An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.

Keough MB, Rogers JA, Zhang P, Jensen SK, Stephenson EL, Chen T, Hurlbert MG, Lau LW, Rawji KS, Plemel JR, Koch M, Ling CC, Yong VW.

Nat Commun. 2016 Apr 26;7:11312. doi: 10.1038/ncomms11312.

27.

Demyelination induces transport of ribosome-containing vesicles from glia to axons: evidence from animal models and MS patient brains.

Shakhbazau A, Schenk GJ, Hay C, Kawasoe J, Klaver R, Yong VW, Geurts JJ, van Minnen J.

Mol Biol Rep. 2016 Jun;43(6):495-507. doi: 10.1007/s11033-016-3990-2. Epub 2016 Apr 26.

PMID:
27115494
28.

Activity-Dependent and Experience-Driven Myelination Provide New Directions for the Management of Multiple Sclerosis.

Jensen SK, Yong VW.

Trends Neurosci. 2016 Jun;39(6):356-365. doi: 10.1016/j.tins.2016.04.003. Epub 2016 Apr 21. Review.

PMID:
27113322
29.

Immunosenescence of microglia and macrophages: impact on the ageing central nervous system.

Rawji KS, Mishra MK, Michaels NJ, Rivest S, Stys PK, Yong VW.

Brain. 2016 Mar;139(Pt 3):653-61. doi: 10.1093/brain/awv395. Epub 2016 Jan 29. Review.

30.

Expanding antigen-specific regulatory networks to treat autoimmunity.

Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, Tsai S, Wang J, Garabatos N, Izquierdo C, Agrawal S, Keough MB, Yong VW, James E, Moore A, Yang Y, Stratmann T, Serra P, Santamaria P.

Nature. 2016 Feb 25;530(7591):434-40. doi: 10.1038/nature16962. Epub 2016 Feb 17.

PMID:
26886799
31.

Monocytes increase human cardiac myofibroblast-mediated extracellular matrix remodeling through TGF-β1.

Mewhort HE, Lipon BD, Svystonyuk DA, Teng G, Guzzardi DG, Silva C, Yong VW, Fedak PW.

Am J Physiol Heart Circ Physiol. 2016 Mar 15;310(6):H716-24. doi: 10.1152/ajpheart.00309.2015. Epub 2016 Jan 22.

32.

Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types.

Zhang Y, Jonkman L, Klauser A, Barkhof F, Yong VW, Metz LM, Geurts JJ.

Mult Scler. 2016 Oct;22(12):1569-1577. Epub 2016 Jan 11.

PMID:
26754802
33.

1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis.

Sloka S, Zhornitsky S, Silva C, Metz LM, Yong VW.

PLoS One. 2015 Dec 17;10(12):e0144084. doi: 10.1371/journal.pone.0144084. eCollection 2015.

34.

Fluorescent Phosphorus Dendrimer as a Spectral Nanosensor for Macrophage Polarization and Fate Tracking in Spinal Cord Injury.

Shakhbazau A, Mishra M, Chu TH, Brideau C, Cummins K, Tsutsui S, Shcharbin D, Majoral JP, Mignani S, Blanchard-Desce M, Bryszewska M, Yong VW, Stys PK, van Minnen J.

Macromol Biosci. 2015 Nov;15(11):1523-34. doi: 10.1002/mabi.201500150. Epub 2015 Jul 14.

PMID:
26175127
35.

Detecting deoxyhemoglobin in spinal cord vasculature of the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis using susceptibility MRI and hyperoxygenation.

Nathoo N, Rogers JA, Yong VW, Dunn JF.

PLoS One. 2015 May 18;10(5):e0127033. doi: 10.1371/journal.pone.0127033. eCollection 2015.

36.

The role of EMMPRIN in T cell biology and immunological diseases.

Hahn JN, Kaushik DK, Yong VW.

J Leukoc Biol. 2015 Jul;98(1):33-48. doi: 10.1189/jlb.3RU0215-045R. Epub 2015 May 14. Review.

PMID:
25977287
37.

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.

Zhornitsky S, Johnson TA, Metz LM, Weiss S, Yong VW.

J Neuroinflammation. 2015 Mar 19;12:55. doi: 10.1186/s12974-015-0278-8.

38.

Experimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin.

Keough MB, Jensen SK, Yong VW.

J Vis Exp. 2015 Mar 26;(97). doi: 10.3791/52679.

39.

Inefficient clearance of myelin debris by microglia impairs remyelinating processes.

Lampron A, Larochelle A, Laflamme N, Préfontaine P, Plante MM, Sánchez MG, Yong VW, Stys PK, Tremblay MÈ, Rivest S.

J Exp Med. 2015 Apr 6;212(4):481-95. doi: 10.1084/jem.20141656. Epub 2015 Mar 16.

40.

The promise of futility trials in neurological diseases.

Koch MW, Korngut L, Patry DG, Agha-Khani Y, White C, Sarna JR, Yeung M, Yong VW, Heng DY, Cutter G, Metz L.

Nat Rev Neurol. 2015 May;11(5):300-5. doi: 10.1038/nrneurol.2015.34. Epub 2015 Mar 17. Review.

PMID:
25776824
41.

ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Sarkar S, Zemp FJ, Senger D, Robbins SM, Yong VW.

Neuro Oncol. 2015 Aug;17(8):1095-105. doi: 10.1093/neuonc/nou362. Epub 2015 Feb 1.

42.

EMMPRIN, an upstream regulator of MMPs, in CNS biology.

Kaushik DK, Hahn JN, Yong VW.

Matrix Biol. 2015 May-Jul;44-46:138-46. doi: 10.1016/j.matbio.2015.01.018. Epub 2015 Jan 31. Review.

43.

Stimulation of monocytes, macrophages, and microglia by amphotericin B and macrophage colony-stimulating factor promotes remyelination.

Döring A, Sloka S, Lau L, Mishra M, van Minnen J, Zhang X, Kinniburgh D, Rivest S, Yong VW.

J Neurosci. 2015 Jan 21;35(3):1136-48. doi: 10.1523/JNEUROSCI.1797-14.2015.

44.

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.

Mishra MK, Wang J, Keough MB, Fan Y, Silva C, Sloka S, Hayardeny L, Brück W, Yong VW.

Ann Clin Transl Neurol. 2014 Jun;1(6):409-22. doi: 10.1002/acn3.67. Epub 2014 May 26.

45.

The battle for the brain: Brain tumor-initiating cells vs. microglia/macrophages.

Sarkar S, Yong VW.

Oncoimmunology. 2014 Feb 14;3:e28047. eCollection 2014.

46.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

47.

Changes in tissue directionality reflect differences in myelin content after demyelination in mice spinal cords.

Ansari MK, Yong HY, Metz L, Yong VW, Zhang Y.

J Struct Biol. 2014 Nov;188(2):116-22. doi: 10.1016/j.jsb.2014.09.009. Epub 2014 Oct 1.

PMID:
25281497
48.

Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells.

Sarkar S, Döring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, Dunn JF, Kinniburgh D, van Rooijen N, Robbins S, Forsyth P, Cairncross G, Weiss S, Yong VW.

Ann Neurosci. 2013 Oct;20(4):154. doi: 10.5214/ans.0972.7531.200407. No abstract available.

49.

Interactions between microglia and T cells in multiple sclerosis pathobiology.

Strachan-Whaley M, Rivest S, Yong VW.

J Interferon Cytokine Res. 2014 Aug;34(8):615-22. doi: 10.1089/jir.2014.0019. Review.

PMID:
25084178
50.

Iron in multiple sclerosis: roles in neurodegeneration and repair.

Stephenson E, Nathoo N, Mahjoub Y, Dunn JF, Yong VW.

Nat Rev Neurol. 2014 Aug;10(8):459-68. doi: 10.1038/nrneurol.2014.118. Epub 2014 Jul 8. Review.

PMID:
25002107

Supplemental Content

Support Center